DAIICHI SANKYO, INC.
- Country
- ๐ฏ๐ตJapan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13
- Registration Number
- NCT01468467
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธUniversity of Minnesota, Minneapolis, Minnesota, United States
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 19
- Registration Number
- NCT01390337
- Locations
- ๐บ๐ธ
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธJohns Hopkins Medical Institute, Baltimore, Maryland, United States
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 42
- Registration Number
- NCT01364844
- Locations
- ๐บ๐ธ
Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 38
- Registration Number
- NCT01349036
- Locations
- ๐บ๐ธ
University California, Los Angeles, Los Angeles, California, United States
๐บ๐ธUniversity California, San Francisco, San Francisco, California, United States
๐บ๐ธDana Faber Cancer Institute, Boston, Massachusetts, United States
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 90
- Registration Number
- NCT01349049
- Locations
- ๐บ๐ธ
UCSF Helen Diller Family Family Comprehensive Cancer Center, San Francisco, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
- Conditions
- Advanced Ovarian CancerAdvanced Solid Malignant Tumors
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 36
- Registration Number
- NCT01290471
- Locations
- ๐บ๐ธ
Karmanos Cancer Center, Detroit, Michigan, United States
๐บ๐ธUniv. Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 88
- Registration Number
- NCT01287858
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study of DS-2248 in Participants With Advanced Solid Tumors
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 60
- Registration Number
- NCT01288430
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT01260584
- Locations
- ๐บ๐ธ
Sanai Center for Thrombosis Research, Baltimore, Maryland, United States
๐บ๐ธMedpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
๐บ๐ธThe Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States
Colesevelam for Children With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 236
- Registration Number
- NCT01258075